2. Disease Areas
  3. Cancer Blood or Cardio-cerebrovascular Disease
  4. Leukemia/Lymphoma/Myeloma Blood Disease
  5. Leukemia/Lymphoma/Myeloma
  6. Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is a heterogeneous, indolent lymphoproliferative neoplasm characterized by the accumulation of monoclonal, mature-appearing B lymphocytes in the blood, bone marrow, and lymphoid tissues. It is the most common leukemia in adults in the Western hemisphere, arising from a clonal expansion of mature B cells with distinct immunoglobulin gene rearrangements. CLL and small lymphocytic lymphoma (SLL) are considered manifestations of the same disease at different stages, differing primarily by the extent of peripheral blood and bone marrow involvement. The disease exhibits significant clinical and molecular diversity, with some patients experiencing a slow, asymptomatic course while others develop aggressive, rapidly progressing disease. Genetic markers such as IGHV mutation status, del(13q), del(11q), del(17p), and trisomy 12 contribute to prognostic stratification. CLL is associated with immune dysfunction, including hypogammaglobulinemia and autoimmune complications, which stem from the clonal B-cell origin. Although the exact etiology remains unclear, risk factors include age, family history, and genetic predisposition, with the disease being rare in children and predominantly affecting older adults. Diagnosis relies on flow cytometry, peripheral blood smear, and clinical evaluation, with treatment strategies tailored to disease stage, symptoms, and molecular features—ranging from observation to chemotherapy, targeted therapies (e.g., BTK inhibitors, BCL-2 inhibitors), and immunotherapy. Despite advances, CLL remains incurable, but effective management can induce remission and prolong survival.

Chronic Lymphocytic Leukemia (10):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N0913
    Manninotriose 13382-86-0 99.97%
    Manninotriose is a binder of dihydrofolate reductase and thymidylate synthase. Manninotriose binds to dihydrofolate reductase via hydrogen bond formation with Arg28. Manninotriose binds to thymidylate synthase via hydrogen bond formation with Arg50. Manninotriose acts as a membrane protectant and helps improve stress tolerance. Manninotriose can be used in research related to acute lymphoblastic leukemia.
    Manninotriose
  • HY-183689
    OAT-4828 2947497-65-4
    OAT-4828 is an orally active ubiquitin-specific protease 7 (USP7) inhibitor with an IC50 of 32 nM. OAT-4828 induces antileukemic activity in B-cell-derived non-Hodgkin's lymphoma models via inhibition of USP7. OAT-4828 is applicable to research related to chronic lymphocytic leukemia.
    OAT-4828
  • HY-12974A
    PRT-060318 dihydrochloride 3032567-93-1 98.98%
    PRT-060318 (PRT318) dihydrochloride is a potent, selective and orally active tyrosine kinase Syk inhibitor with an IC50 of 3 nM. PRT-060318 dihydrochloride suppresses chronic lymphocytic leukemia (CLL) B cell activation and migration, and induces apoptosis. PRT-060318 dihydrochloride prevents Heparin (HY-17567)-induced thrombocytopenia and thrombosis in a transgenic mouse model. PRT-060318 dihydrochloride can be used for CLL and thrombus research.
    PRT-060318 dihydrochloride
  • HY-17600A
    Acalabrutinib maleate 2242394-65-4
    Acalabrutinib (Calquence) maleate is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib maleate demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL). Acalabrutinib maleate can be used for CLL research. Acalabrutinib maleate is a click chemistry reagent, which contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Acalabrutinib maleate
  • HY-180967
    PROTAC BCR-ABL Degrader-2 2703834-25-5
    PROTAC BCR-ABL Degrader-2 is a selective Bcr-AblT315 PROTAC degrader with a DC50 of 108.7 nM in Ba/F3 Bcr-AblT315I cells. PROTAC BCR-ABL Degrader-2 exhibits the most potent degradation efficacy with DR of 69.89% and 94.23% at 100 and 300 nM, respectively. PROTAC BCR-ABL Degrader-2 demonstrates high plasma exposure, and induces significant tumor regression and induces tumor cell apoptosis with a good safety profile in vivo. PROTAC BCR-ABL Degrader-2 can be used for chronic myeloid leukemia (CML) research.
    PROTAC BCR-ABL Degrader-2
  • HY-P992439
    PF-06747143
    PF-06747143 is recombinant anti-human antibody targeting CXCR4. PF-06747143 blocks CXCL12-induced calcium flux, F-actin polymerization, chemotaxis, cell migration, and leukemic cell bone marrow homing. PF-06747143 reduces tumor burden and improves survival in mouse models of hematologic malignancies. PF-06747143 can be used for the research of chronic lymphocytic leukemia, acute myeloid leukemia, and hematologic malignancies.
    PF-06747143
  • HY-119159
    AS1604498 361465-74-9
    AS1604498 is a highly specific competitive inhibitor of human NAMPT, with an IC50 of 44.4 nM. AS1604498 functionally inhibits NAMPT enzymatic activity, reduces nicotinamide mononucleotide production, decreases intracellular NAD levels, activates caspase 3/7 and induces cancer cell apoptosis. AS1604498 is applicable to research related to chronic myeloid leukemia.
    AS1604498
  • HY-N17588
    9-O-Angeloyl-8-methoxythymol 361541-62-0
    9-O-Angeloyl-8-methoxythymol is a thymol derivative and cytotoxin, with a IC50 value of 13.1 μg/mL against human myeloid leukemia cells, a IC50 value of 31.8 μg/mL against human lymphoblastic leukemia cells, and a IC50 >40 μg/mL against colon cancer and lymphoma cells. 9-O-Angeloyl-8-methoxythymol is applicable to leukemia-related research.
    9-O-Angeloyl-8-methoxythymol
  • HY-N16866
    Gossypetin 3,8,3′-trimethyl ether 14965-08-3
    Gossypetin 3,8,3′-trimethyl ether is a natural flavonoid.
    Gossypetin 3,8,3′-trimethyl ether
  • HY-P991744
    Anti-Mouse CXCR4 Antibody (Cx4Mab-1)
    Anti-Mouse CXCR4 Antibody is a monoclonal antibody that specifically recognizes murine CXCR4 (C-X-C chemokine receptor 4), also known as fusin or CD184. CXCR4 is a seven-transmembrane G protein–coupled receptor whose principal endogenous ligand is CXCL12 (stromal cell–derived factor-1α, SDF-1α) and is widely expressed in hematopoietic cells, endothelial cells, neurons, as well as embryonic and adult stem cells. The CXCR4–CXCL12 signaling axis activates multiple downstream pathways, including ERK1/2, Ras, p38 MAPK, PLC/MAPK, and SAPK/JNK, thereby regulating cell survival, proliferation, migration, and stemness maintenance. Aberrant overexpression of CXCR4 is closely associated with poor prognosis and metastasis in various cancers, with CXCR4-positive tumor cells preferentially home to CXCL12-rich tissues such as the liver, bone marrow, lung, and lymph nodes. Accordingly, CXCR4 and its CXCL12-related antagonists emerge as attractive targets for experimental anticancer therapy. Anti-Mouse CXCR4 Antibody is generated using a cell-based immunization and screening strategy and exhibits high affinity for both endogenous and exogenous murine CXCR4. Anti-Mouse CXCR4 Antibody can be used for thestudy of chronic lymphocytic leukemia and multiple myeloma.
    Anti-Mouse CXCR4 Antibody (Cx4Mab-1)